Mediwound, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $25.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors surrounding Mediwound’s strategic positioning and potential upcoming agreements. A significant factor is the anticipated new agreement with the Biomedical Advanced Research and Development Authority (BARDA) for NexoBrid, which could provide substantial financial benefits through product procurement and funding for further development initiatives.
Additionally, Jennings highlights the potential of NexoBrid as the only FDA-approved enzymatic debridement agent for severe burn injuries, positioning Mediwound and its partner VCEL as likely beneficiaries of a government request for proposals. The likelihood of securing this contract is high, given the specific nature of the request and the absence of competing products, making the cancellation of the contract the only unlikely scenario that could prevent this outcome.
According to TipRanks, Jennings is a 4-star analyst with an average return of 3.0% and a 51.71% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Abbott Laboratories.
In another report released on July 18, H.C. Wainwright also maintained a Buy rating on the stock with a $31.00 price target.